Sorrento Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
460.10
3,825.00
4,590.00
8,152.00
151,856.00
21,193
Cost of Goods Sold (COGS) incl. D&A
1,294.80
4,388.00
3,107.00
3,696.00
11,025.00
10,069
Gross Income
834.70
563.00
1,483.00
4,456.00
140,831.00
11,124
SG&A Expense
14,847.40
33,970.00
51,475.00
64,354.00
88,494.00
140,601
EBIT
15,682.10
34,533.00
49,992.00
59,898.00
52,337.00
129,477
Unusual Expense
5,985.50
209.00
27,373.00
31,581.00
31,277.00
26,207
Non Operating Income/Expense
-
-
69,274.00
27,549.00
1,006.00
1,387
Interest Expense
253.20
1,629.00
1,652.00
1,610.00
4,980.00
57,631
Pretax Income
21,911.30
36,359.00
13,760.00
64,833.00
15,315.00
213,781
Income Tax
-
1,702.00
36,314.00
896.00
36,038.00
6,274
Equity in Affiliates
-
-
-
-
40,244.00
5,019
Consolidated Net Income
21,911.30
34,657.00
50,074.00
63,937.00
11,038.00
212,526
Net Income
21,911.30
34,657.00
45,811.00
60,923.00
9,061.00
203,540
Net Income After Extraordinaries
21,911.30
34,657.00
45,811.00
60,923.00
9,061.00
203,540
Net Income Available to Common
21,911.30
34,657.00
45,811.00
60,923.00
9,061.00
203,540
EPS (Basic)
1.46
1.30
1.24
1.21
0.13
1.92
Basic Shares Outstanding
15,045.70
26,679.00
36,909.00
50,360.00
69,742.00
106,150
EPS (Diluted)
1.46
1.30
1.24
1.21
0.13
1.92
Diluted Shares Outstanding
15,045.70
26,679.00
36,909.00
50,360.00
70,381.00
106,150
EBITDA
14,391.70
31,349.00
47,622.00
57,013.00
59,417.00
120,423
Non-Operating Interest Income
9.60
12.00
24.00
272.00
241.00
921
Minority Interest Expense
-
-
4,263.00
3,014.00
1,977.00
8,986
Equity in Affiliates (Pretax)
-
-
4,041.00
435.00
-
-
Other After Tax Income (Expense)
-
-
-
-
71.00
-
About Sorrento Therapeutics
View Profile
